
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VLA2001,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Valneva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Albumedix and Valneva Expand Collaboration to Include Newly Approved Inactivated COVID-19 Vaccine
Details : Albumedix Recombumin® rHA is an essential component in VLA2001, used in the manufacturing process and final formulation of the vaccine. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 14, 2022
Lead Product(s) : VLA2001,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Valneva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
